Could Nabriva Therapeutics plc (NBRV) Recover After Forming a Bearish Multiple Bottom Chart Pattern?

March 16, 2018 - By Stephen Andrade

The stock of Nabriva Therapeutics plc (NBRV) shows a multiple bottoms pattern with $5.41 target or 6.00 % below today’s $5.75 share price. The 8 months chart pattern indicates high risk for the $210.98 million company. It was reported on Mar, 16 by If the $5.41 price target is reached, the company will be worth $12.66 million less.
Multiple bottoms are very good trading chart patterns. These patterns have a low break even failure rate and decent average rise in a bull market, giving them a solid performance rank. Back-tests of such patterns show that the break even failure rate is 4%, the average rise: 37%, the throwback rate: 64% and the percentage of stocks meeting their price targets: 64%.

The stock increased 1.05% or $0.06 during the last trading session, reaching $5.75. About 50,099 shares traded. Nabriva Therapeutics plc (NASDAQ:NBRV) has risen 15.31% since March 16, 2017 and is uptrending. It has underperformed by 1.39% the S&P500.

Analysts await Nabriva Therapeutics plc (NASDAQ:NBRV) to report earnings on March, 23. They expect $-0.55 earnings per share, up 20.29 % or $0.14 from last year’s $-0.69 per share. After $-0.66 actual earnings per share reported by Nabriva Therapeutics plc for the previous quarter, Wall Street now forecasts -16.67 % EPS growth.

Nabriva Therapeutics plc (NASDAQ:NBRV) Ratings Coverage

Among 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nabriva Therapeutics has $22 highest and $10 lowest target. $15.60’s average target is 171.30% above currents $5.75 stock price. Nabriva Therapeutics had 8 analyst reports since October 12, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Thursday, October 27 by Leerink Swann. Needham initiated the shares of NBRV in report on Monday, October 12 with “Buy” rating. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) earned “Outperform” rating by RBC Capital Markets on Thursday, November 12. The rating was initiated by Wedbush with “Outperform” on Tuesday, October 13. Wedbush maintained it with “Outperform” rating and $13 target in Wednesday, February 1 report. The stock of Nabriva Therapeutics plc (NASDAQ:NBRV) earned “Outperform” rating by RBC Capital Markets on Tuesday, October 13. On Wednesday, January 27 the stock rating was initiated by Gabelli with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.